With all due respect, here's how it makes sense.

With all due respect, here's how it makes sense.

First, one has to stop thinking like a long who has been here for so many years and does truly understand what we are confident that leronlimab can do for so many people in so many indications.

Second, one has to remember that CYDY has not, for a myriad of reasons, some their own fault, some maybe not as much, given the FDA what they have asked for. Oh sure, they give like 70%, but that is not getting the job done. Bottom line, management has not made leronlimab irrefutable.

Third, one can only hope that the new(ish) management team will move things forward quickly and efficiently, give the FDA what they want, make the results irrefutable, and get leronlimab to the masses for multiple indications. Or, in the alternative, if current management realizes that they either cannot or are not interested in doing such things on their own, we can only hope they will bring in a good partner who will.